OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc
OptiBiotix Health (OPTI.L) Extension of territories for Seed Health’s DS-01
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
OptiBiotix Health (OPTI.L) Trading and commercial update
OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes,provides the following unaudited preliminary revenue figures for the first six months ended 30 June
TPI provides its latest research note on OptiBiotix Health plc (OPTI.L).
OptiBiotix Health plc, the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and cardiovascular health, is now in a pivotal position.
OptiBiotix Health (OPTI.L) Head of Quality & Operations appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces the appointment of Aneta Zlotkowska as Head of Quality & Operations.
OptiBiotix Health (OPTI.L) FDA Investigational New Drug authorisation
FDA Investigational New Drug authorisation for product containing LPLDL®